Higher serum MOG protein levels associated with MS diagnosis and disease activity compared to controls

This case-control study evaluated serum myelin oligodendrocyte glycoprotein (MOG) protein levels in a population of multiple sclerosis (MS) patients, healthy donors, and patients with other neurological diseases. The primary outcome assessed the association between serum MOG protein levels and MS diagnosis and disease activity. Secondary outcomes included the correlation between serum MOG and neurofilament light (NfL) levels, though specific results for this correlation were not detailed in the provided data.

Results indicated that serum MOG protein levels were higher in MS patients compared to healthy donors, with a mean difference of 20.5 pg/ml (95% CI 12.7, 28.2). When compared to patients with other neurological diseases, serum MOG levels remained higher in the MS group, showing a mean difference of 27.5 pg/ml (95% CI 17.5, 40.5). Additionally, serum MOG levels were higher in MS patients experiencing clinical relapse compared to those in clinical remission, with a mean difference of 15.3 pg/ml (95% CI 6.11, 25.6).

No safety data, adverse events, or tolerability information were reported for this study, as the investigation focused on biomarker levels rather than therapeutic interventions. The study design limits causal inference, and the authors note that questions remain about the significance and usefulness of blood MOG protein levels in MS. These limitations suggest that while the biomarker distinguishes MS from controls and correlates with relapse, its clinical utility requires further validation.

This evidence is observational and does not establish causality. The findings may inform future research into biomarker utility but should not currently alter diagnostic or management practices without further confirmation. Clinicians should interpret these results with caution regarding their immediate applicability to patient care.